{"id":"folfox-folfiri-with-bevacizumab","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Hypertension"},{"rate":"5-10","effect":"Bleeding/hemorrhage"},{"rate":"5-10","effect":"Thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin, irinotecan) are cytotoxic chemotherapy combinations that damage DNA and inhibit cell proliferation. Bevacizumab is a monoclonal antibody targeting VEGF (vascular endothelial growth factor) that prevents angiogenesis, reducing blood supply to tumors and enhancing chemotherapy efficacy.","oneSentence":"FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:21.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"First-line treatment of advanced colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07221357","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Untreated, Unresectable, or Metastatic Colorectal Cancer","enrollment":990},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT06663319","phase":"PHASE1","title":"A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-15","conditions":"Colorectal Neoplasms, Gastrointestinal Neoplasms","enrollment":220},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT07193862","phase":"EARLY_PHASE1","title":"Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-12-10","conditions":"Colorectal Cancer Metastatic","enrollment":10},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT07323576","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2026-02-01","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT06106308","phase":"PHASE2","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff Oncology","startDate":"2024-02-27","conditions":"Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation","enrollment":113},{"nctId":"NCT06838338","phase":"PHASE1","title":"JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jian Li","startDate":"2025-03-20","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT05836324","phase":"PHASE1","title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-24","conditions":"Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":408},{"nctId":"NCT07150403","phase":"PHASE2","title":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-12-31","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":74},{"nctId":"NCT06936527","phase":"PHASE1, PHASE2","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","status":"ENROLLING_BY_INVITATION","sponsor":"NovaOnco Therapeutics Co., Ltd.","startDate":"2025-05-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation","enrollment":102},{"nctId":"NCT07106034","phase":"PHASE2","title":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pudong Hospital","startDate":"2025-08-31","conditions":"Advanced Colorectal Cancer","enrollment":32},{"nctId":"NCT06856187","phase":"PHASE2","title":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-28","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":119},{"nctId":"NCT05480306","phase":"PHASE2","title":"Phase 2 Study of DKN-01 in Colorectal Cancer","status":"COMPLETED","sponsor":"Leap Therapeutics, Inc.","startDate":"2022-08-30","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer","enrollment":188},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT06843954","phase":"PHASE4","title":"Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mohammed Mahmood Mohammed","startDate":"2022-09-01","conditions":"Colo-rectal Cancer","enrollment":157},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06833866","phase":"PHASE1","title":"Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-04","conditions":"Advanced or Metastatic CRC","enrollment":33},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT01878422","phase":"PHASE3","title":"Sequential Treatment Strategy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":376},{"nctId":"NCT05894694","phase":"PHASE4","title":"Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2023-09-27","conditions":"Advanced Colorectal Carcinoma","enrollment":320},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT05039944","phase":"PHASE2","title":"SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies","status":"TERMINATED","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-11-30","conditions":"Colorectal Cancer","enrollment":7},{"nctId":"NCT03250832","phase":"PHASE1","title":"Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-08-08","conditions":"Neoplasms","enrollment":111},{"nctId":"NCT06293014","phase":"PHASE2","title":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-23","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT01606098","phase":"PHASE3","title":"The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2012-07","conditions":"Colon Cancer, Primary Tumour, Rectal Cancer","enrollment":206},{"nctId":"NCT05861505","phase":"PHASE3","title":"COLLISION RELAPSE Trial","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-04-24","conditions":"Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer","enrollment":360},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT00655499","phase":"PHASE2","title":"Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-06","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT01442935","phase":"PHASE2","title":"Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2011-02","conditions":"Colorectal Cancer","enrollment":256},{"nctId":"NCT00984048","phase":"","title":"Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2009-08","conditions":"Colorectal Cancer","enrollment":160},{"nctId":"NCT04831528","phase":"","title":"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-04-10","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT02015923","phase":"PHASE4","title":"Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-12","conditions":"Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer","enrollment":107},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT01417494","phase":"PHASE2","title":"1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2011-07","conditions":"Colorectal Cancer","enrollment":102},{"nctId":"NCT01858649","phase":"PHASE2","title":"Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-05","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT03641976","phase":"PHASE2","title":"A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-01-03","conditions":"Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV","enrollment":120},{"nctId":"NCT00265850","phase":"PHASE3","title":"Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-11","conditions":"Colorectal Cancer","enrollment":2334},{"nctId":"NCT02339116","phase":"PHASE3","title":"Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2015-02-26","conditions":"Metastatic Colorectal Cancer","enrollment":654},{"nctId":"NCT03022734","phase":"PHASE2","title":"Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-09","conditions":"Rectal Cancer, Metastatic","enrollment":40},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT02069704","phase":"PHASE1","title":"Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2014-10-29","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":142},{"nctId":"NCT01900717","phase":"PHASE2","title":"Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-07","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":102},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT00911170","phase":"PHASE3","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-03","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":847},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT00636610","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-05","conditions":"Metastatic Colorectal Cancer","enrollment":199},{"nctId":"NCT01322815","phase":"PHASE2","title":"A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2010-10","conditions":"Colon Cancer","enrollment":11},{"nctId":"NCT01320683","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2011-03","conditions":"Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer","enrollment":1},{"nctId":"NCT00411450","phase":"PHASE2","title":"Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":116},{"nctId":"NCT01030042","phase":"PHASE3","title":"Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients","status":"COMPLETED","sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","startDate":"2009-09","conditions":"Metastatic Colorectal Cancer","enrollment":110},{"nctId":"NCT00959647","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-09","conditions":"Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer","enrollment":19},{"nctId":"NCT01077739","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72},{"nctId":"NCT00598156","phase":"PHASE3","title":"Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":249},{"nctId":"NCT00615056","phase":"PHASE2","title":"A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03","conditions":"Colorectal Neoplasms","enrollment":171},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- bevacizumab","- irinotecan","- leucovorin","- 5-fluorouracil","- oxaliplatin"],"phase":"phase_3","status":"active","brandName":"FOLFOX/ FOLFIRI with bevacizumab","genericName":"FOLFOX/ FOLFIRI with bevacizumab","companyName":"Dutch Colorectal Cancer Group","companyId":"dutch-colorectal-cancer-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX/FOLFIRI chemotherapy regimens combined with bevacizumab inhibit tumor cell division and block new blood vessel formation to starve tumors of nutrients. Used for Metastatic colorectal cancer, First-line treatment of advanced colorectal cancer.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}